Your browser doesn't support javascript.
loading
Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma.
Jin, Yi; Chen, Kenian; De Paepe, Ayla; Hellqvist, Eva; Krstic, Aleksandra D; Metang, Lauren; Gustafsson, Charlotte; Davis, Richard E; Levy, Yair M; Surapaneni, Rakesh; Wallblom, Ann; Nahi, Hareth; Mansson, Robert; Lin, Yin C.
Afiliación
  • Jin Y; Baylor Institute for Immunology Research, Baylor Scott & White Research Institute, Dallas, TX.
  • Chen K; Baylor Institute for Immunology Research, Baylor Scott & White Research Institute, Dallas, TX.
  • De Paepe A; Center for Hematology and Regenerative Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Hellqvist E; Center for Hematology and Regenerative Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Krstic AD; Center for Hematology and Regenerative Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Metang L; Baylor Institute for Immunology Research, Baylor Scott & White Research Institute, Dallas, TX.
  • Gustafsson C; Center for Hematology and Regenerative Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Davis RE; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Levy YM; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.
  • Surapaneni R; Scott & White Vasicek Cancer Treatment Center, Baylor Scott & White Health, Temple, TX; and.
  • Wallblom A; Center for Hematology and Regenerative Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Nahi H; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
  • Mansson R; Center for Hematology and Regenerative Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Lin YC; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Blood ; 131(19): 2138-2150, 2018 05 10.
Article en En | MEDLINE | ID: mdl-29519805
ABSTRACT
Multiple myeloma (MM) is an aggressive cancer that originates from antibody-secreting plasma cells. Although genetically and transcriptionally well characterized, the aberrant gene regulatory networks that underpin this disease remain poorly understood. Here, we mapped regulatory elements, open chromatin, and transcription factor (TF) footprints in primary MM cells. In comparison with normal antibody-secreting cells, MM cells displayed consistent changes in enhancer activity that are connected to superenhancer (SE)-mediated deregulation of TF genes. MM cells also displayed widespread decompaction of heterochromatin that was associated with activation of regulatory elements and in a major subset of patients' deregulation of the cyclic adenosine monophosphate pathway. Finally, building SE-associated TF-based regulatory networks allowed identification of several novel TFs that are central to MM biology. Taken together, these findings significantly add to our understanding of the aberrant gene regulatory network that underpins MM.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cromatina / Regulación Neoplásica de la Expresión Génica / Elementos de Facilitación Genéticos / Ensamble y Desensamble de Cromatina / Redes Reguladoras de Genes / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Año: 2018 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cromatina / Regulación Neoplásica de la Expresión Génica / Elementos de Facilitación Genéticos / Ensamble y Desensamble de Cromatina / Redes Reguladoras de Genes / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Año: 2018 Tipo del documento: Article